TRIAL DETAIL
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 11/13/2007 |
Age of Trial (yrs) 17.4 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
XL820-201 |
|||
Sponsor: |
Exelixis |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
Randomized |
|||
IV or Oral: |
Oral |
|||
Trial Notes: |
XL820 is a novel small molecule inhibitor of the receptor tyrosine kinases KIT, VEGFR2, and PDGFR-α and -β. In preclinical studies, XL820 potently inhibited the resistance-associated activation loop mutations in KIT, and mutations in the ATP binding region of KIT including those in the juxtamembrane domain. XL820 has been investigated in two Phase 1 studies (XL820-001 and XL820-002), and is being evaluated in a multi-center Phase 2 study (XL820-201) of subjects with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib. We understand that this trial has been withdrawn (Dec, 2008). No other information is available at this time. |
|||
Trial Links |
Trial Results |
Drug Information |
| The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1700 Luther Ln |
Park Ridge |
IL |
60068 |
USA |
|
450 Brookline Ave |
Boston |
MA |
02215-5450 |
USA |